Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Raised by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 31.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,000 shares of the company’s stock after acquiring an additional 5,500 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Xeris Biopharma were worth $78,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Barclays PLC increased its stake in shares of Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after acquiring an additional 151,685 shares during the period. Geode Capital Management LLC increased its stake in shares of Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock valued at $9,502,000 after acquiring an additional 93,091 shares during the period. Principal Financial Group Inc. increased its stake in shares of Xeris Biopharma by 30.3% during the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock valued at $292,000 after acquiring an additional 23,843 shares during the period. Quantbot Technologies LP acquired a new position in Xeris Biopharma in the third quarter worth approximately $44,000. Finally, SG Americas Securities LLC grew its position in Xeris Biopharma by 188.5% in the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock worth $172,000 after buying an additional 39,335 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on XERS shares. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Monday, November 11th. Finally, HC Wainwright lifted their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Stock Up 0.6 %

Shares of NASDAQ:XERS opened at $3.60 on Friday. The firm has a fifty day moving average of $3.45 and a two-hundred day moving average of $3.10. The firm has a market capitalization of $536.69 million, a P/E ratio of -8.00 and a beta of 2.61. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $3.87.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.